ReviewHIV/AIDS (Auckland, N.Z.)2020
Drug-Resistant Tuberculosis and HIV Infection: Current Perspectives.
Review in HIV/AIDS (Auckland, N.Z.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05633056 (Adaptive Evaluation of mHealth and Conventional Adherence Support Interventions to Optimize Outcome With New Treatment Regimens for Drug-resistant Tuberculosis and HIV in South Africa), which is not on this map. Cited by 37 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Adaptive Evaluation of mHealth and Conventional Adherence Support Interventions to Optimize Outcome With New Treatment Regimens for Drug-resistant Tuberculosis and HIV in South Africa
Who cites it
37 citing papers in PubMed, 5 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- Molecular detection of rifampicin-resistantFrontiers in medicine · 2024Pooled it
- HIV infection and multidrug resistant tuberculosis: a systematic review and meta-analysis.BMC infectious diseases · 2021Pooled it
- Pooled it
- Pooled it
- Pooled it
- Trial
- HIV-tuberculosis co-infection in Liangshan, a resource-limited region of Southwest China: trends and implications in the context of integrated prevention, 2019-2024.Infectious diseases of poverty · 2026Article
- Predictors of Treatment Outcomes Among HIV-Positive Patients with Drug-Resistant Tuberculosis in Rural Eastern Cape, South Africa: A Retrospective Cohort Study.International journal of environmental research and public health · 2026Article
- Drug resistance patterns and associated risk factors in pulmonary tuberculosis patients from selected hospitals in Ghana.BMC infectious diseases · 2026Article
- Leveraging Different Distance Functions to Predict Antiviral Peptides with Geometric Deep Learning from ESMFold-Predicted Tertiary Structures.Antibiotics (Basel, Switzerland) · 2026Article
- Epidemiology and treatment outcomes of TB-HIV co-infection in a rural South African setting: an exploratory analysis of retreatment and contextual factors.Frontiers in public health · 2026Article
- Global burden of HIV and drug-resistant tuberculosis co-infection and its attributable risk factors, 1990 to 2021, with projections to 2031.BMC infectious diseases · 2025Article
- Clinical and Epidemiological Profile of HIV TB Coinfection Among Adult Male and Female Population Across the City of Pune - A Cross-sectional Observational Study Protocol.Journal of pharmacy & bioallied sciences · 2025Article
- Infection with Mycobacterium tuberculosis alters the antibody response to HIV-1.PLoS pathogens · 2025Article
- Article
- Prevalence of Multidrug-Resistant Tuberculosis and Its Association With Previous Treatment History in Adults.Cureus · 2025Article
- Trends, prevalence, and determinants of unfavorable tuberculosis treatment outcomes among adult patients in Northeast Ethiopia: The race to achieve a 90 % treatment success rate by 2025.Global epidemiology · 2025Article
- Comparing the longer regimen and the shorter regimen for multidrug-resistant pulmonary tuberculosis patients treated under the programmatic management of drug-resistant tuberculosis.Frontiers in medicine · 2025Article
- Predicting Treatment Outcomes in Patients with Drug-Resistant Tuberculosis and Human Immunodeficiency Virus Coinfection, Using Supervised Machine Learning Algorithm.Pathogens (Basel, Switzerland) · 2024Article
- Antibacterial efficacy of mycobacteriophages against virulent Mycobacterium tuberculosis.BMC microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-resistant tuberculosis (DR-TB), including multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), is considered a potential obstacle for elimination of TB globally. HIV coinfection with M/XDR-TB further complicates the scenario, and is a potential threat with challenging management. Reports have shown poor outcomes and alarmingly high mortality rates among people living with HIV (PLHIV) coinfected with M/XDR-TB. This coinfection is also responsible for all forms of M/XDR-TB epidemics or outbreaks. Better outcomes with reductions in mortality have been reported with concomitant treatment containing antiretroviral drugs for the HIV component and antitubercular drugs for the DR-TB component. Early and rapid diagnosis with genotypic tests, prompt treatment with appropriate regimens based on drug-susceptibility testing, preference for shorter regimens fortified with newer drugs, a patient-centric approach, and strong infection-control measures are all essential components in the management of M/XDR-TB in people living with HIV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.